Effect of Tumor Necrosis Factor-α Antagonism in Asthma: a Meta-analysis of the Published Literature
10.1007/sl1596-011-0165-1
- Author:
CHEN XIAOJU
1
;
XIONG LIANG
;
Qin SHOUMING
;
MA WANLI
;
ZHOU QIONG
Author Information
1. Department of Respiratory Diseases, Union Hospital, Key Lab of Pulmonary Diseases of Health Ministry, Tongji Medical College,Huazhong University of Science and Technology, Wuhan 430022, China;The Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, China
- Keywords:
asthma;
immunotherapy;
Meta-analysis;
tumor necrosis factor-α
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2011;31(1):137-141
- CountryChina
- Language:Chinese
-
Abstract:
It remains controversial whether tumor necrosis factor (TNF)-α antagonism is effective for asthma.This meta-analysis was performed to evaluate efficacy of TNF-α antagonism in treatment of patients with asthma.MEDLINE,EMBASE,LILACS,and CINAHL databases were searched for English-language studies published through January 3,2010.Randomized-controlled trials comparing TNF-α antagonism with control therapy were selected.For each report,data were extracted in relation to the outcomes analyzed:asthma exacerbation,asthma quality of life questionnaire scores,and forced expiratory volume in 1 second.Four assessable trials were identified including 641 patients with asthma.TNF-α antagonism therapy was superior to control therapy in preventing exacerbations in asthmatics [pooled odds ratio 0.52 (95％ confidence interval 0.29-0.88),P=0.02]; however,there was a nonsignificant reduction in asthma quality of life questionnaire scores [0.23 (0 to 0.47),P=0.05],forced expiratory volume in 1 second [0.03,(-0.14 to 0.10),P=0.74] when analyzed using standardized mean differences.TNF-α antagonism was superior to control chemotherapy in terms of asthma exacerbation,but not asthma quality of life questionnaire scores or forced expiratory volume in 1 second.
